Source: https://www.nice.org.uk/event/tacd-february-2017
Timestamp: 2017-03-28 06:09:06
Document Index: 65445888

Matched Legal Cases: ['art 2', 'art 2', 'art 2', 'art 2', 'art 2', 'art 1', 'art 1', 'art 2', 'art 2', 'art 2', 'art 2', 'art 2', 'art 2', 'art 1', 'art 1', 'art 2']

Appraisal of collagenase clostridium histolyticum for treating Dupuytren’s contracture – The Committee for Medicinal Products for Human Use (at European Medicines Agency) has not yet given its regulatory opinion for nivolumab and as a consequence this discussion will take place in a Part 2 session (Part 2 sessions are closed to public observers).
4.1. Declarations of interest – Part 2 only (closed session)
4.2. Introduction by the Chair, Professor Gary McVeigh – Part 2 only (closed session)
4.3. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
Appraisal of everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression
5.2. Introduction by the Chair, Professor Gary McVeigh – Part 1 only (open session)
5.3. Presentation by the lead team – Part 1 AND part 2 (open and closed session)
Appraisal of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy – This discussion will focus on a new value proposition submitted by the company. The nature of this discussion is commercially sensitive and will take place in part 2 only (Part 2 sessions are closed to public observers).
6.1. Declarations of interest – Part 2 only (closed session)
6.2. Introduction by the Chair, Professor Gary McVeigh – Part 2 only (closed session)
6.3. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
Appraisal of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs
7.2. Introduction by the Vice Chair, Dr Lindsay Smith – Part 1 only (open session)
7.3. Presentation by the Vice Chair, Dr Lindsay Smith – Part 1 AND part 2 (open and closed session)
The next meeting will take place on Wednesday 29 March 2017 at NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT.
Registration will close on Tuesday 14 February 2017. Please note that it may not be possible to accept late requests. Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Jon Littler.
Registration period: 31 January 2017 to 14 February 2017